Novo Nordisk

Pharmaceuticals

NVO

$ 122 (0.56)%

Share price

$ 544 bn

Market Cap

$ 539 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.01x the weighted average for S&P 500

FY2021

Primary Climate Goal

Proj. YOY change in GHG emissions (Scope 1 + 2)

Stronger than the -9.3% weighted average for S&P 500

FY2022

Novo Nordisk aims to achieve net zero for Scope 1 + 2 by 2030

1.5°C

GHG emissions and Carbon intensity

Novo Nordisk reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 93 Kt (+3/+3.3% y-o-y). At the sime time, carbon intensity was down at 4.1 t (-0.4 /-8.9% y-o-y).

Novo Nordisk's Scope 3 emissions declined to 1,449 Kt (-62 /-4.1% y-o-y). The performance has been erratic recently.

The company is committed to achieving net zero for Scope 1 + 2 by 2030, which translates into the estimated reduction of -10 Kt per annum over the period of FY2022 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2021Q4	93	77	16		22,469	4.1
2020Q4	90	75	15	1,449	19,962	4.5
2019Q4	161	86	75	1,511	18,357	8.8
2018Q4	176			1,464	17,728	9.9
2017Q4				3,055	16,960

Novo Nordisk

Carbon footprint

Primary Climate Goal

Novo Nordisk aims to achieve net zero for Scope 1 + 2 by 2030

GHG emissions and Carbon intensity

Novo Nordisk's carbon footprint

Company environmental metrics